Evidence map›Paper›PMID 23821743›Full record

ArticleJournal of lipid research2013

Prostaglandin reductase-3 negatively modulates adipogenesis through regulation of PPARγ activity.

Yu-Hsiang Yu, Yi-Cheng Chang, Tseng-Hsiung Su, Jiun-Yi Nong, Chao-Chin Li, Lee-Ming Chuang

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. 15-keto-PGEiScience · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.Journal of the American Society of Nephrology : JASN · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yu-Hsiang YuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
Yi-Cheng Chang
Tseng-Hsiung Su
Jiun-Yi Nong
Chao-Chin Li
Lee-Ming Chuang
National Taiwan University Hospital · TWGenomics Research Center, Academia Sinica · TWAcademia Sinica · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adipocyte differentiation is a multistep program under regulation by several factors. Peroxisome proliferator-activated receptor γ (PPARγ) serves as a master regulator of adipogenesis. However, the endogenous ligand for PPARγ remained elusive until 15-keto-PGE2 was identified recently as an endogenous PPARγ ligand. In this study, we demonstrate that zinc-containing alcohol dehydrogenase 2 (ZADH2; here termed prostaglandin reductase-3, PTGR-3) is a new member of prostaglandin reductase family that converts 15-keto-PGE2 to 13,14-dihydro-15-keto-PGE2. Adipogenesis is accelerated when endogenous PTGR-3 is silenced in 3T3-L1 preadipocytes, whereas forced expression of PTGR-3 significantly decreases adipogenesis. PTGR-3 expression decreased during adipocyte differentiation, accompanied by an increased level of 15-keto-PGE2. 15-keto-PGE2 exerts a potent proadipogenic effect by enhancing PPARγ activity, whereas overexpression of PTGR-3 in 3T3-L1 preadipocytes markedly suppressed the proadipogenic effect of 15-keto-PGE2 by repressing PPARγ activity. Taken together, these findings demonstrate for the first time that PTGR-3 is a novel 15-oxoprostaglandin-Δ(13)-reductase and plays a critical role in modulation of normal adipocyte differentiation via regulation of PPARγ activity. Thus, modulation of PTGR-3 might provide a novel avenue for treating obesity and related metabolic disorders.

Indexed as

AdipogenesisAdipocytesAdipose Tissue, WhiteAdiposityAnimalsCell LineDinoprostoneMiceObesityOxidoreductases Acting on CH-CH Group DonorsPPAR gamma15-keto-13,14-dihydroprostaglandin E215-ketoprostaglandin E2DinoprostoneOxidoreductases Acting on CH-CH Group DonorsPPAR gammaprostaglandin reductase-3, mouseadipocyte differentiationeicosanoidligandnuclear receptor

Identifiers

PMID23821743
PMCPMC3735937
OpenAlexW2107358582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.